T6735 |
XL413 hydrochloride
|
2062200-97-7
|
99.82%
|
|
XL413 hydrochloride (BMS-863233 Hydrochloride) is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC 50 of 3.4 nM. XL413 hydrochloride also ex...
|
T4417 |
LDC-4297 HCl (1453834-21-3(free base))
|
T4417
|
99.81%
|
|
LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.
|
T21588 |
Olomoucine
|
101622-51-9
|
99.80%
|
|
Olomoucine is an ATP competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3 and 25 µM, re...
|
T10742 |
CDK9-IN-10
|
3542-63-0
|
99.8%
|
|
CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
|
T6239 |
Palbociclib monohydrochloride
|
827022-32-2
|
99.79%
|
|
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 ad...
|
T72039 |
CLK1-IN-3
|
2922550-28-3
|
99.79%
|
|
Clk1-in-3 is a + selective and highly potent sexual Clk1 inhibitor with an IC50 of 5 nM and 300 pairs higher affinity than Dyrk1A. CLK1-IN-3 also showed highly e...
|
T23867 |
Cdc7-IN-7c
|
1330781-04-8
|
99.77%
|
|
Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.
|
T2463 |
ML141
|
71203-35-5
|
99.77%
|
|
ML141 (CID-2950007) is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).
|
T1785 |
Palbociclib
|
571190-30-2
|
99.76%
|
|
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has i...
|
T16363 |
NVP-2
|
1263373-43-8
|
99.76%
|
|
NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50...
|
T1912 |
Dinaciclib
|
779353-01-4
|
99.73%
|
|
Dinaciclib (SCH 727965) is a new-type and effective CDK inhibitor for CDK2/5/1/9 (IC50: 1 nM/1 nM/3 nM/4 nM) with potential antineoplastic activity.
|
T6081 |
Milciclib
|
802539-81-7
|
99.73%
|
|
Milciclib (PHA-848125) (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4...
|
T11878 |
LRRK2 inhibitor 1
|
1802525-61-6
|
99.73%
|
|
LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.
|
T10736 |
CDK4/6-IN-2
|
1800506-48-2
|
99.7%
|
|
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
|
T13202 |
Trilaciclib hydrochloride
|
1977495-97-8
|
99.69%
|
|
Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).
|
T17069 |
THAL-SNS-032
|
2139287-33-3
|
99.68%
|
|
THAL-SNS-032 is a selective CDK9 degrader PROTAC.
|
T36964 |
BML-259
|
267654-00-2
|
99.68%
|
|
BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenera...
|
T6205 |
AT7519
|
844442-38-2
|
99.67%
|
|
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
|
T6126 |
JNJ-7706621
|
443797-96-4
|
99.66%
|
|
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2.
|
T5200 |
Indirubin-3'-monoxime
|
160807-49-8
|
99.65%
|
|
Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin...
|